SVRA Savara, Inc.
Listings ·
Savara stockholders approved doubling authorized common stock to 600,000,000 shares. The 8-K gives no reason for the increase, and it also reports a new CFO and COO effective July 15, 2026, after the current CFO resigns for health reasons.
As amended, the loan agreement provides for up to $105 million of term loans, and the added draws depend on FDA approval of MOLBREEVI for aPAP. Two covenant compliance dates move to April 1, 2027 and September 30, 2027.
Savara priced 23,809,524 shares at $4.20, below the $4.41 last sale price, and pre-funded warrants for 7,142,857 more. Jefferies, Piper Sandler and Guggenheim Securities are joint book-running managers, and Polsinelli PC is the company's counsel.
Savara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024.
Savara drew the first $30 million of a loan of up to $200 million from a group led by Hercules Capital, and used it to repay its Silicon Valley Bank term loan. Later draws depend on FDA approval of MOLBREEVI, a revenue milestone or lender approval.
Savara is a company whose sole product candidate is molgramostim inhalation solution, which it calls MOLBREEVI. The company says it is substantially dependent on the clinical, regulatory and commercial success of MOLBREEVI. Its risk disclosures note that clinical development is lengthy and expensive, with an uncertain outcome, and that regulatory approval for an investigational new drug may be conditioned, delayed or denied. The filing says that if a competitor obtains Orphan Drug exclusivity for a product with the same active ingredient and route of delivery for autoimmune pulmonary alveolar proteinosis, the company may be unable to market its candidate until that exclusivity expires. Savara also depends on third-party suppliers and manufacturers, and it must maintain compliance with covenants under its long-term debt instruments. The company says it may need to establish or maintain collaborations or obtain additional funding. It also notes that approval of MOLBREEVI may bring regulatory requirements and that weak market acceptance would limit revenue from sales.
| Product or program | What it is | Stage |
|---|---|---|
| MOLBREEVI (molgramostim) | Inhalation solution for autoimmune pulmonary alveolar proteinosis |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $81.4 million | $78.0 million |
| Net income (loss) | -$118.8 million | -$95.9 million |
| Cash from operations | -$101.0 million | -$89.1 million |
| Cash and equivalents | $33.2 million | $15.1 million |
| Short-term investments | $202.5 million | $181.2 million |
Our latest story on this, dated Oct 29, 2025: "Savara prices $130.0 million stock offering at $4.20 per share". The story links the filing or release it is based on. Read the story.
Savara, Inc. trades under the ticker SVRA on NASDAQ.
Savara, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:YB4P; LSX:A2DQ2B.
The SEC Central Index Key (CIK) for Savara, Inc. is 1160308. Its filings are on SEC EDGAR.
205,460,015 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Savara, Inc. under United States.
Our directory classifies Savara, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Savara, Inc. is US8051111016.
aibio.space lists Savara, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Savara is a company whose sole product candidate is molgramostim inhalation solution, which it calls MOLBREEVI. The company says it is substantially dependent on the clinical, regulatory and commercial success of MOLBREEVI.
MOLBREEVI (molgramostim): Inhalation solution for autoimmune pulmonary alveolar proteinosis
Savara, Inc. reported a net loss of $118.8 million for the fiscal year ended Dec 31, 2025, and used $101.0 million of cash in operations, per its annual report to the SEC.
$81.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$173.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio